Manufacturer record

Firstmed Therapeutics Pvt Ltd: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

4 batches manufactured by Firstmed Therapeutics Pvt Ltd were declared Not of Standard Quality between April 2025 and August 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

4 records linked to Firstmed Therapeutics Pvt Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
4Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Apr 2025 to Aug 2025

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

4
NSQ batches since 2025
4
Products affected
Other
Most common failure
Aug 2025
Latest alert

Flagged batches per year

2025 · 4

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Rabeprazole Sodium Tablets IP FLRL-0004Mfg 2025-04 · Exp 2027-03 Incorrect labellingLabelling DTL, PuducherryState lab Aug 2025
Paracetamol And Aceclofenac Tablets FAPS-2057Mfg 2025-02 · Exp 2027-01 Incorrect labellingLabelling DTL, PuducherryState lab Aug 2025
Montelukast Sodium & Levocetirizine Hydrochloride Tablets IP(Moncube LC) FDMC-588Mfg 2024-07 · Exp 2026-06 For the received sample Montelukast Sodium & Levocetirizine Hydrochloride Tablets IP (Moncube LC) ,Presence of Spots was observed which should not be presentOther State Lab PuducherryState lab Apr 2025
Glypro 1 (Glimepiride Tablets IP) 1mg FGYO-1626Mfg 2024-12 · Exp 2026-11 Sample does not conform to IP specification for Glimepiride Tablets with respect to the content of GlimepirideOther DTL MaduraiState lab Apr 2025

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.